Personalized medicine to heart
Research on cardiovascular genetics has had some spectacular successes in uncovering new therapeutic targets—for example, the finding that people with inactivating mutations in the gene encoding the trafficking protein PCSK9 are at a much lower risk for heart attacks led to the development of antibody therapy targeting this protein. However, when it comes to personalizing treatment for cardiovascular disease on the basis of an individual patient's genetic makeup or biomarker data, there are currently only a handful of options where such an approach has proven to be clinically useful.
Related Conference of Personalized medicine to heart
June 22-23, 2026
5th World Congress on Medicinal Chemistry and Computer Aided Drug Design
Paris, France
July 27-28, 2026
19th International Conference and Exhibition on Pharmacovigilance & Drug Safety
Rome, Italy
July 27-28, 2026
26th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry
Rome, Italy
August 20-21, 2026
27th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
London, UK
August 20-21, 2026
29th International Conference and Exhibition on Pharmaceutical Formulations
London, UK
August 20-21, 2026
32nd International Conference on Advanced Clinical Research and Clinical Trials
London, UK
November 19-20, 2026
14th International Conference and Exhibition on Natural Products and Medicinal Plants Research
Dubai, UAE
November 26-27, 2026
5th World Conference on Pharma Industry and Medical Devices
Zurich, Switzerland